Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on May 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Amendment adds XOMA Royalty Holdings Corporation as a formal merger-party, advancing Ligand’s proposed acquisition structure.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Amendment adds XOMA Royalty Holdings Corporation as a formal merger-party, advancing Ligand’s proposed acquisition structure
- HoldCo would survive as Ligand’s wholly owned subsidiary after Merger Sub’s merger
- Transaction remains subject to XOMA Royalty stockholder approval and regulatory conditions
- Closing risk includes competing offers, integration challenges, transaction costs, litigation, and failure to realize expected benefits
- Investors should monitor XOMA Royalty’s forthcoming preliminary and definitive proxy statements for consideration and voting details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.